A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
AT132 has prompted more safety concerns, this time at a lower dose than before.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.